USPTO serial 79330273
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Greger
Jeffrey H. Greger STUDEBAKER BRACKETT PLLC8255 Greensboro DriveSuite 300Tysons, VA 22102| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products and preparations for prevention, treatment and immune therapy and combinations of prevention, treatment and immune therapy of infectious diseases and allergic diseases, as well as pharmaceutical products and preparations against cancer; vaccines; and medicines for human use for prevention, treatment and immune therapy and combinations of prevention, treatment and immune therapy of infectious diseases, allergic diseases and cancer; bacterial and viral vaccines, synthetic, recombinant, peptide, protein, RNA-, DNA- and therapeutic vaccines; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibodies; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibody drug conjugates | ACTIVE | — |
| 010 | Apparatus and containers for the administration of vaccines and medicines, namely, cups for dispensing medicine, injection needles for the administration of vaccines and medicines, injection instruments without needles for the administration of vaccines and medicines, nose sprayers for medical purposes, and spray syringes for medical purposes; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibodies; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibody drug conjugates | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 12, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 21, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 21, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 16, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 16, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 16, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 28, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 28, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 27, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 8, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 8, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 8, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 20, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 20, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 20, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 20, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 20, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 6, 2023 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Oct 3, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 3, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 3, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 27, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jun 7, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 16, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 16, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 1, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 31, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 11, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 7, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 6, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |